Vincerx Pharma, Inc. (VINC) Misses Q3 EPS by 25c

Vincerx Pharma, Inc. (NASDAQ: VINC) reported Q3 EPS of ($0.80), $0.25 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Vincerx Pharma, Inc. (VINC) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c